Using the HDAC inhibitor vorinostat plus the VEGF inhibitor bevacizumab resulted in clinical activity in patients with clear cell renal cell carcinoma.
Active surveillance prior to initiating targeted therapy might benefit patients with metastatic renal cell carcinoma, since it delays therapy and toxicities.
Computer-assisted tumor objective response evaluations for patients with metastatic renal cell carcinoma can save time and reduce errors.
Dacomitinib induction therapy has shown activity in HPV-negative, locally advanced or metastatic penile squamous cell carcinoma.
In this interview we discuss a new study that looked at the outcomes of patients with small renal masses who were followed with active surveillance.
Intravesical rAd-IFNα/Syn3 showed promising response rates, a tolerable treatment schedule, and acceptable toxicity among patients with high-grade, nonmuscle-invasive bladder cancer, refractory or relapsed after bacillus Calmette-Guérin therapy.
Pembrolizumab is associated with longer overall survival and fewer treatment-related toxicities vs chemotherapy for patients with advanced urothelial carcinoma.
The Decipher prostate cancer gene-expression classifier can predict patients’ risk of metastasis and prostate cancer-specific mortality using biopsy specimens prior to radical prostatectomy or radiotherapy plus androgen deprivation.
Suspicious pathology from kidney tumors was significantly associated with testing positive for fumarate hydratase mutations, which may aid in the early diagnosis of hereditary leiomyomatosis and renal cell carcinoma.
Though it is used infrequently, lymph node dissection with higher yield of lymph nodes is associated with lower all-cause mortality among patients with urothelial carcinoma of the upper urinary tract who undergo nephroureterectomy.